- Dubai Struggles to Ease Debt Fears; Investors Rattled
- Asian Stocks Likely to Fall After Europe Selloff
- US Companies Already Moving on Curbing Emissions
- Fannie Mae to Tighten Lending Standards: Report
- Investing in Good Karma – and Making a Profit
- Retailers Should Believe in Christmas Miracles
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Where Do Pardoned Turkeys Go?
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Car insurance scofflaws raise health mandate doubt
- Peach farmers block Greek highway
- Perry leads Texas GOP fight against climate bill
- Robotic hamsters are holidays' unlikely new craze
- Bookstore chain Borders UK appoints administrators
- Tommy Hilfiger's estate in Conn. sells for $20M
- Repsol says it will invest $1.5 billion in Bolivia
- Belgium reluctant to renew GM loan offer
- Business software firm RedPrairie files for IPO
Text Size 
WOODCLIFF LAKE, N.J. - Par Pharmaceutical Co. said Monday it received marketing approval for a generic version of Johnson & Johnson's extended-release chronic pain drug Ultram ER, and has started shipping the drug.
The Food and Drug Administration approved Par's generic in doses of 100 milligrams and 200 milligrams, Par said. Rival generic drugmakers will not be able to start selling their versions for 180 days because Par was the first company to seek approval.
Annual U.S. sales of Ultram ER, or tramadol, are about $156 million, Par said. In morning trading, Par stock rose 68 cents, or 3 percent, to $23.51.
Ultram ER is sold by Johnson & Johnson's Ortho-McNeill division. Shares of New Brunswick, N.J.-based Johnson & Johnson rose 55 cents to $61.98.
Print
Email
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Ever wished your cab driver would stop nattering and just get to where you're going? Well that moment is near(er).
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
Data is a real-time snapshot *Data is delayed at least 15 minutes